Advertising
Agriculture
Airlines-Aviation
Aerospace-Defense
Art
Auto
Banking-Financial Services
Beer, Wine & Spirits
Biometrics
Biotechnology
Books
Charity
Chemical
Computer Electronics
Computer Gaming
Computer Hardware
Computer Networks
Computer Software
Construction-Building
Consumer Electronics
Death Care Services
Education
Electronic Commerce
Electronic Components
Electronic Design Automation
Electronics Performance Measurement
Entertainment
Environmental Services
Fashion
Film-Motion-Picture
Food-Beverages
Gambling-Casinos
Government
Health Care-Hospitals
High-Tech Security
Higher Education
Homeland Security
Household-Consumer-Cosmetics
Infectious Disease Control
Insurance
Internet Technology
Legal
Leisure-Travel-Hotels
Machinery
Magazines
Maritime-Shipbuilding
Medical-Pharmaceuticals
Mining-Metals
Mobile Entertainment
Multimedia-Online-Internet
Music
Mutual Funds
Nanotechnology
Office Products
Oil-Energy
Otc-Smallcap
Paper-Forest-Products-Containers
Peripherals
Publishing-Information Services
Radio
Real Estate
Religion
Restaurants
Retail
Safety
Semiconductors
Sports
Supermarkets
Supplementary Medicine
Telecommunications
Television
Temporary Staffing Services
Textiles
Tobacco
Transportation-Trucking-Railroad
Travel
Utilities
Workforce Management/Human Resources
News Releases For May 26, 2009

Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018

ProCure Treatment Centers to Equip Chicago Facility With Software Solutions From Elekta

Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

Medinox Announces Clinical Results of Naproxen Prodrug

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

Microtest Laboratories is an Industry Leader in ICH Stability Testing

Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue

Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2009 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.